Gastroesophageal Junction Carcinoma — Trials

Gastroesophageal Junction Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

706 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 231
Recruiting: 126
Ph III recruiting: 18
Growth YoY: +44.2%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (86)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07818070	A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma	not yet recruiting	Phase 3	600	Ono Pharmaceutical Co., Ltd.INDUSTRY	0	Sep 14, 2026	clinicaltrials
NCT07603349	Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma	not yet recruiting	Phase 2 / Phase 3	405	Nanfang Hospital, Southern Medical UniversityOTHER